Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03915964




Registration number
NCT03915964
Ethics application status
Date submitted
12/04/2019
Date registered
16/04/2019
Date last updated
30/05/2024

Titles & IDs
Public title
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis
Scientific title
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Secondary ID [1] 0 0
I4V-MC-JAJA
Secondary ID [2] 0 0
17172
Universal Trial Number (UTN)
Trial acronym
RA-BRIDGE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Baricitinib
Treatment: Drugs - TNF Inhibitor

Experimental: Baricitinib Low Dose - Baricitinib administered orally.

Experimental: Baricitinib High Dose - Baricitinib administered orally.

Active Comparator: TNF Inhibitor - Adalimumab or etanercept administered subcutaneously (SC) per standard of care.


Treatment: Drugs: Baricitinib
Administered orally.

Treatment: Drugs: TNF Inhibitor
Administered SC
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time from First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE)
Timepoint [1] 0 0
Baseline through Study Completion (Approximately 5.5 Years)
Secondary outcome [1] 0 0
Time from First Dose of Study Treatment to First Arterial Thromboembolic Event (ATE)
Timepoint [1] 0 0
Baseline through Study Completion (Approximately 5.5 Years)
Secondary outcome [2] 0 0
Time from First Dose of Study Treatment to First Major Adverse Cerebro-Cardiovascular Event (MACE)
Timepoint [2] 0 0
Baseline through Study Completion (Approximately 5.5 Years)
Secondary outcome [3] 0 0
Time from First Dose of Study Treatment to First Malignancy (excluding nonmelanoma skin cancer [NMSC])
Timepoint [3] 0 0
Baseline through Study Completion (Approximately 5.5 Years)
Secondary outcome [4] 0 0
Time from First Dose of Study Treatment to First Opportunistic Infection
Timepoint [4] 0 0
Baseline through Study Completion (Approximately 5.5 Years)
Secondary outcome [5] 0 0
Time from First Dose of Study Treatment to First Serious Infection
Timepoint [5] 0 0
Baseline through Study Completion (Approximately 5.5 Years)

Eligibility
Key inclusion criteria
- Participants must have at least one of the following characteristics:

- Documented evidence of a VTE prior to this study

- At least 60 years of age

- A body mass index (BMI) greater than or equal to 30 kilograms per meter squared
(kg/m²), or

- Age 50 to less than 60 years and BMI 25 to less than 30 kg/m².

- Participants must have an inadequate response or intolerance to at least 1
disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Participant should have no reason to not take a TNF inhibitor.

- Participants must not be pregnant or breastfeeding.

- Participants must not have had more than one VTE.

- Participants must not have cancer.

- Participants must not have active herpes zoster, serious infection, active
tuberculosis, or any other serious illness.

- Participants must not have had a live vaccine within four weeks of study start.

- Participants must not have participated in any other clinical trial within four weeks
of study start.

- Participants must not have a history of IV drug use, other illicit drug abuse, or
chronic alcohol abuse in the past year.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2026
Actual
Sample size
Target
2600
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,VIC
Recruitment hospital [1] 0 0
Optimus Clinical Research - Botany
Recruitment hospital [2] 0 0
Genesis Research Services - Newcastle
Recruitment hospital [3] 0 0
Rheumatology Research Unit - Maroochydore
Recruitment hospital [4] 0 0
Southern Clinical Research - Hobart
Recruitment hospital [5] 0 0
Emeritus Research - Camberwell
Recruitment postcode(s) [1] 0 0
2019 - Botany
Recruitment postcode(s) [2] 0 0
2292 - Newcastle
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
7000 - Hobart
Recruitment postcode(s) [5] 0 0
3124 - Camberwell
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Montana
Country [17] 0 0
United States of America
State/province [17] 0 0
Nebraska
Country [18] 0 0
United States of America
State/province [18] 0 0
Nevada
Country [19] 0 0
United States of America
State/province [19] 0 0
New Hampshire
Country [20] 0 0
United States of America
State/province [20] 0 0
New Mexico
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Oklahoma
Country [24] 0 0
United States of America
State/province [24] 0 0
Pennsylvania
Country [25] 0 0
United States of America
State/province [25] 0 0
South Dakota
Country [26] 0 0
United States of America
State/province [26] 0 0
Texas
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
West Virginia
Country [29] 0 0
Austria
State/province [29] 0 0
Wien
Country [30] 0 0
Belgium
State/province [30] 0 0
Bruxelles-Capitale, Région De
Country [31] 0 0
Belgium
State/province [31] 0 0
Limburg
Country [32] 0 0
Belgium
State/province [32] 0 0
Vlaams Gewest
Country [33] 0 0
Czechia
State/province [33] 0 0
Brno-mesto
Country [34] 0 0
Czechia
State/province [34] 0 0
Jihomoravský Kraj
Country [35] 0 0
Czechia
State/province [35] 0 0
Moravskoslezský Kraj
Country [36] 0 0
Czechia
State/province [36] 0 0
Ostrava Mesto
Country [37] 0 0
Czechia
State/province [37] 0 0
Pardubický Kraj
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 10
Country [39] 0 0
Czechia
State/province [39] 0 0
Praha, Hlavní Mešto
Country [40] 0 0
Czechia
State/province [40] 0 0
Zlínský Kraj
Country [41] 0 0
Czechia
State/province [41] 0 0
Praha 11
Country [42] 0 0
Czechia
State/province [42] 0 0
Praha 4
Country [43] 0 0
Denmark
State/province [43] 0 0
Midtjylland
Country [44] 0 0
Denmark
State/province [44] 0 0
Syddanmark
Country [45] 0 0
France
State/province [45] 0 0
Alpes-Maritimes
Country [46] 0 0
France
State/province [46] 0 0
Alsace
Country [47] 0 0
France
State/province [47] 0 0
Aquitaine
Country [48] 0 0
France
State/province [48] 0 0
Centre
Country [49] 0 0
France
State/province [49] 0 0
Haute-Garonne
Country [50] 0 0
France
State/province [50] 0 0
La Roche-sur-Yon
Country [51] 0 0
France
State/province [51] 0 0
Rhône-Alpes
Country [52] 0 0
France
State/province [52] 0 0
Caluire-et-Cuire
Country [53] 0 0
France
State/province [53] 0 0
Paris
Country [54] 0 0
Germany
State/province [54] 0 0
Hessen
Country [55] 0 0
Germany
State/province [55] 0 0
Mecklenburg-Vorpommern
Country [56] 0 0
Germany
State/province [56] 0 0
Nordrhein-Westfalen
Country [57] 0 0
Germany
State/province [57] 0 0
Sachsen-Anhalt
Country [58] 0 0
Germany
State/province [58] 0 0
Berlin
Country [59] 0 0
Germany
State/province [59] 0 0
Hamburg
Country [60] 0 0
Greece
State/province [60] 0 0
Attikí
Country [61] 0 0
Greece
State/province [61] 0 0
Kentrikí Makedonía
Country [62] 0 0
Greece
State/province [62] 0 0
Évros
Country [63] 0 0
Hungary
State/province [63] 0 0
Borsod-Abauj-Zemplen
Country [64] 0 0
Hungary
State/province [64] 0 0
Pest
Country [65] 0 0
Hungary
State/province [65] 0 0
Veszprém City
Country [66] 0 0
Hungary
State/province [66] 0 0
Debrecen
Country [67] 0 0
Israel
State/province [67] 0 0
HaDarom
Country [68] 0 0
Israel
State/province [68] 0 0
HaMerkaz
Country [69] 0 0
Israel
State/province [69] 0 0
Tell Abib
Country [70] 0 0
Israel
State/province [70] 0 0
Haifa
Country [71] 0 0
Israel
State/province [71] 0 0
?eifa
Country [72] 0 0
Italy
State/province [72] 0 0
Abruzzo
Country [73] 0 0
Italy
State/province [73] 0 0
Toscana
Country [74] 0 0
Italy
State/province [74] 0 0
Firenze
Country [75] 0 0
Italy
State/province [75] 0 0
Napoli
Country [76] 0 0
Italy
State/province [76] 0 0
Verona
Country [77] 0 0
Lithuania
State/province [77] 0 0
Kauno Miestas
Country [78] 0 0
Lithuania
State/province [78] 0 0
Siauliai
Country [79] 0 0
Lithuania
State/province [79] 0 0
Vilnius
Country [80] 0 0
Netherlands
State/province [80] 0 0
Fryslân
Country [81] 0 0
Netherlands
State/province [81] 0 0
Limburg
Country [82] 0 0
Poland
State/province [82] 0 0
Kujawsko-pomorskie
Country [83] 0 0
Poland
State/province [83] 0 0
Lubelskie
Country [84] 0 0
Poland
State/province [84] 0 0
Lubuskie
Country [85] 0 0
Poland
State/province [85] 0 0
Mazowieckie
Country [86] 0 0
Poland
State/province [86] 0 0
Podlaskie
Country [87] 0 0
Poland
State/province [87] 0 0
Pomorskie
Country [88] 0 0
Poland
State/province [88] 0 0
Warminsko-Mazurki
Country [89] 0 0
Poland
State/province [89] 0 0
Wielkopolskie
Country [90] 0 0
Poland
State/province [90] 0 0
Slaskie
Country [91] 0 0
Puerto Rico
State/province [91] 0 0
Caguas
Country [92] 0 0
Puerto Rico
State/province [92] 0 0
Ponce
Country [93] 0 0
Puerto Rico
State/province [93] 0 0
San Juan
Country [94] 0 0
Romania
State/province [94] 0 0
Bra?ov
Country [95] 0 0
Romania
State/province [95] 0 0
Braila
Country [96] 0 0
Romania
State/province [96] 0 0
Bucure?ti
Country [97] 0 0
Romania
State/province [97] 0 0
Ia?i
Country [98] 0 0
Romania
State/province [98] 0 0
Maramures
Country [99] 0 0
Romania
State/province [99] 0 0
Valcea
Country [100] 0 0
Romania
State/province [100] 0 0
Galati
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Kurskaya Oblast
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Leningradskaya Oblast'
Country [103] 0 0
Russian Federation
State/province [103] 0 0
Moskovskaya Oblast
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Moskva
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Nizhegorodskaya Oblast
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Ryazanskaya Oblast
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Sankt-Peterburg
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Tul'skaya Oblast'
Country [109] 0 0
Russian Federation
State/province [109] 0 0
Ul'yanovskaya Oblast
Country [110] 0 0
Russian Federation
State/province [110] 0 0
Yaroslavskaya Oblast'
Country [111] 0 0
Russian Federation
State/province [111] 0 0
Moscow
Country [112] 0 0
Russian Federation
State/province [112] 0 0
Petrozavodsk
Country [113] 0 0
Russian Federation
State/province [113] 0 0
Saratov
Country [114] 0 0
Slovakia
State/province [114] 0 0
Banskobystrický Kraj
Country [115] 0 0
Slovakia
State/province [115] 0 0
Bratislavský Kraj
Country [116] 0 0
Slovakia
State/province [116] 0 0
Košický Kraj
Country [117] 0 0
Slovakia
State/province [117] 0 0
Nitriansky Kraj
Country [118] 0 0
Slovakia
State/province [118] 0 0
Trenciansky Kraj
Country [119] 0 0
South Africa
State/province [119] 0 0
Eastern Cape
Country [120] 0 0
South Africa
State/province [120] 0 0
Free State
Country [121] 0 0
South Africa
State/province [121] 0 0
Gauteng
Country [122] 0 0
South Africa
State/province [122] 0 0
Kwazulu-Natal
Country [123] 0 0
South Africa
State/province [123] 0 0
Western Cape
Country [124] 0 0
Spain
State/province [124] 0 0
A Coruña [La Coruña]
Country [125] 0 0
Spain
State/province [125] 0 0
Alicante
Country [126] 0 0
Spain
State/province [126] 0 0
Catalunya [Cataluña]
Country [127] 0 0
Spain
State/province [127] 0 0
Galicia [Galicia]
Country [128] 0 0
Spain
State/province [128] 0 0
Madrid, Comunidad De
Country [129] 0 0
Spain
State/province [129] 0 0
País Vasco
Country [130] 0 0
Spain
State/province [130] 0 0
Pontevedra [Pontevedra]
Country [131] 0 0
Spain
State/province [131] 0 0
Córdoba
Country [132] 0 0
Spain
State/province [132] 0 0
Madrid
Country [133] 0 0
Spain
State/province [133] 0 0
Sevilla
Country [134] 0 0
Switzerland
State/province [134] 0 0
Basel-Stad
Country [135] 0 0
Switzerland
State/province [135] 0 0
Sankt Gallen
Country [136] 0 0
Switzerland
State/province [136] 0 0
Fribourg
Country [137] 0 0
Turkey
State/province [137] 0 0
Edirne
Country [138] 0 0
Turkey
State/province [138] 0 0
Istanbul
Country [139] 0 0
Turkey
State/province [139] 0 0
Izmir
Country [140] 0 0
Turkey
State/province [140] 0 0
Konya
Country [141] 0 0
United Kingdom
State/province [141] 0 0
Bournemouth
Country [142] 0 0
United Kingdom
State/province [142] 0 0
Devon
Country [143] 0 0
United Kingdom
State/province [143] 0 0
England
Country [144] 0 0
United Kingdom
State/province [144] 0 0
Essex
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Hampshire
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Kingston Upon Hull
Country [147] 0 0
United Kingdom
State/province [147] 0 0
North Tyneside
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Nottinghamshire
Country [149] 0 0
United Kingdom
State/province [149] 0 0
Waltham Forest
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Liverpool
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Eli Lilly and Company
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Incyte Corporation
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This post-marketing study is designed to compare the safety of baricitinib versus tumor
necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when
given to participants with rheumatoid arthritis.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03915964
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/ct2/show/NCT03915964